Innate Pharma S.A. (IPHA)
| Market Cap | 130.26M -25.3% |
| Revenue (ttm) | 11.21M -22.4% |
| Net Income | -54.22M |
| EPS | -0.57 |
| Shares Out | 93.70M |
| PE Ratio | n/a |
| Forward PE | 28.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,679 |
| Open | 1.430 |
| Previous Close | 1.425 |
| Day's Range | 1.380 - 1.430 |
| 52-Week Range | 1.170 - 2.710 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 6.67 (+372.84%) |
| Earnings Date | Sep 17, 2026 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $6.67, which is an increase of 372.84% from the latest price.
News
Innate Pharma Q3 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the com...
Innate Pharma Earnings Call Transcript: Q3 2026
The portfolio advanced with TELLOMAK-3 initiation, an effective $75 million Sobi upfront payment, and €96.8 million in cash supporting a runway through Q1 2028. IPH4502 data are due in November 2026 and PACIFIC-9 results are expected in H1 2027.
Innate Pharma Earnings release: Q3 2026
Innate Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q3 2026
Innate Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Innate Pharma Slides: Q3 2026
Innate Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Innate Pharma Reports Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine mon...
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously...
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
Innate Pharma (IPHA) announced that AstraZeneca (AZN) has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second…
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the exp...
Innate Pharma SA: Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today anno...
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.
Innate Pharma SA: Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p...
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update.
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi...
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi...
Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22
The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6....
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript
Lacutamab advances toward accelerated approval as ADC pipeline expands.
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and comp...
Innate Pharma Earnings Call Transcript: Q2 2026
Strategic partnerships and financing have strengthened the balance sheet, enabling advancement of key programs including lacutamab, IPH4502, and monalizumab. Multiple clinical catalysts are expected in H2 2026, with cash runway projected through Q1 2028.
Innate Pharma Earnings release: Q2 2026
Innate Pharma released its Q2 2026 earnings on September 17, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q2 2026
Innate Pharma released its Q2 2026 earnings on September 17, 2026, summarizing the period's financial results.
Innate Pharma Quarterly report: Q2 2026
Innate Pharma has published its Q2 2026 quarterly earnings report on September 17, 2026.
Innate Pharma Slides: Q2 2026
Innate Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 17, 2026.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.